Pregabalin Capsule
Product Images NDC 72162-1548

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1548). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621548)

Pregabalin Capsules, USP 300 mg oral capsules label. The label includes NDC 72162-1548-9, repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by ScieGen Pharmaceuticals Inc. It indicates a package size of 90 capsules and includes storage instructions and child-resistant closure information.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. Four lines represent different treatments: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The x-axis is percent improvement in pain; the y-axis is percent of patients improved.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved against the percent improvement in pain from baseline for Pregabalin 100 mg three times a day and placebo. The graph shows two lines representing these groups, with the y-axis labeled 'Percent of Patients Improved' and the x-axis labeled 'Percent Improvement in Pain from Baseline.' Vertical reference lines appear at various percent improvement intervals.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line chart illustrating percent of patients improved versus percent improvement in pain from baseline. Curves represent Pregabalin at 75 mg, 150 mg, and 300 mg taken twice daily, as well as a placebo group. The graph compares pain improvement outcomes across these groups.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing percent improvement in pain from baseline with the percent of patients improved for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows three curves indicating the proportion of patients achieving various levels of pain improvement, with Pregabalin 200 mg generally showing higher patient improvement percentages than 100 mg and placebo.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line chart comparing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The chart shows three curves representing these groups, illustrating patient response distribution across varying levels of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across different dosages of a medication versus placebo in two studies labeled E1 and E3. The x-axis lists dosage groups including placebo and various daily doses, while the y-axis shows responder rate percentages from 0% to 60%. Bars indicate increasing responder rates with higher dosages, with some marked as statistically significant versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response line graph illustrating seizure reduction as median percentage change from baseline on the y-axis against dose in mg/day on the x-axis. The graph compares results from four studies labeled Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID, showing significant seizure reduction at various doses, all with p-values indicating statistical significance. The zero dose corresponds to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent improvement in pain from baseline on the horizontal axis and percent of patients improved on the vertical axis. It compares four groups: Pregabalin 800mg daily dose, Pregabalin 450mg daily dose, Pregabalin 300mg daily dose, and placebo, illustrating the relation between dosage and patient improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the percentage of subjects without LTR (loss to remission) over 180 days between Pregabalin and placebo groups. The y-axis shows the estimated percentage of subjects without LTR from 0% to 100%, and the x-axis shows days from 0 to 180. The Pregabalin group maintains a higher percentage over time compared to the placebo group.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over baseline to Week 12 BOCF for Pregabalin versus placebo. The y-axis represents percent of subjects improved, ranging from 0 to 100%, and the x-axis shows percent improved from baseline, ranging from 0 to 100. The solid line indicates Pregabalin, showing consistently higher improvement rates than the dotted line representing placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved between Pregabalin and placebo from baseline to week 16. The x-axis shows the percent improvement, and the y-axis shows the percent of subjects improved. Pregabalin shows higher improvement rates across the range compared to placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on patient's age, weight, serum creatinine, and a gender adjustment factor for females. The formula is presented as an equation with numeric constants and variables in parentheses.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing its molecular arrangement with labeled functional groups typical for the active ingredient in the Pregabalin medication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.